In our cohort, integrating four prespecified axes—tumor burden, mucin/tumor phenotype, cytokine-driven inflammation, and systemic immune balance yielded superior discrimination for early response and independent prognostic value for survival, with consistent performance across FIGO I/II and III/IVA strata. This evidence concerns the gene MUC5AC and neoplasm.